BIOSTATISTICS SHARED RESOURCE (BSR) The Biostatistics Shared Resource (BSR) provides collaborative statistical support to Consortium members across each of the Research Programs. We emphasize the importance of establishing ongoing and continuing collaboration with biostatisticians as a means of maximizing scientific collaborations that lead to impactful cancer research. The BSR aids members with projects that do not have dedicated funding for biostatistical support. In addition, the BSR assists members across all Programs in the development of grant proposals. It is expected that such proposals will have biostatistical support built into the budget, in which case ? if a grant is awarded ? a funded collaboration with a biostatistician would subsequently take place outside the auspices of the BSR. In this sense, the BSR frequently spawns NIH-funded research. The BSR is composed of six faculty- level statisticians and three masters-level statisticians, and the CCSG currently funds roughly 1.1 FTE. The level of support for each biostatistician of the BSR ranges from 5-20%, as each biostatistician is primarily funded by research grants and contracts independent of their BSR activities. The CCSG-supported effort ensures that a stable staff of highly skilled biostatisticians is available to Consortium investigators. The members of the BSR have many years of experience working collaboratively with clinical, population, and laboratory scientists and possess a wide range of expertise in statistical methods that are relevant to the Consortium, including clinical trial design (Phase I through Phase III), survival analysis (including competing risks), longitudinal data, diagnostics testing, biomarkers, prediction models, microbiome, genomic, proteomic, metabolomic, high-dimensional data analysis, multi-omic and data-integration methods, analysis of nonlinear time series including modeling and inference with ordinary differential equations, cancer survivorship, inverse- probability weighting, statistical genetics, biological pathway analysis, mixed model and kernel methods, quantile regression, and causal inference.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853656
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications